See more : RONESANS GAYRIMENKUL YAT. (RGYAS.IS) Income Statement Analysis – Financial Results
Complete financial analysis of Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Johnson Chemical Pharmaceutical Works Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Carrier Global Corporation (CARR) Income Statement Analysis – Financial Results
- Builders FirstSource, Inc. (BLDR) Income Statement Analysis – Financial Results
- Gibson Energy Inc. (GBNXF) Income Statement Analysis – Financial Results
- Patriot Battery Metals Inc. (PMET.TO) Income Statement Analysis – Financial Results
- CS Holdings Co., Ltd. (000590.KS) Income Statement Analysis – Financial Results
Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jcpjohnson.com.tw
About Johnson Chemical Pharmaceutical Works Co., Ltd.
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials, and products in Taiwan. The company offers its products in various therapeutic areas, including central nervous system, respiratory, cardiovascular, gastrointestinal, endocrine system, vitamin, anti-inflammatory, cough and cold, pain reliever, etc. It provides its products in the solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. Johnson Chemical Pharmaceutical Works Co., Ltd. was incorporated in 1959 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 606.71M | 494.67M | 411.49M | 424.02M | 425.34M |
| Cost of Revenue | 362.08M | 290.29M | 239.57M | 231.83M | 233.89M |
| Gross Profit | 244.63M | 204.38M | 171.92M | 192.18M | 191.45M |
| Gross Profit Ratio | 40.32% | 41.32% | 41.78% | 45.32% | 45.01% |
| Research & Development | 17.27M | 13.25M | 8.92M | 13.08M | 9.84M |
| General & Administrative | 27.97M | 24.78M | 26.25M | 27.10M | 26.17M |
| Selling & Marketing | 100.48M | 83.67M | 74.47M | 76.47M | 76.55M |
| SG&A | 128.45M | 108.45M | 100.72M | 103.57M | 102.77M |
| Other Expenses | 0.00 | 308.00K | 161.00K | 351.00K | 0.00 |
| Operating Expenses | 145.80M | 121.70M | 109.64M | 116.65M | 112.61M |
| Cost & Expenses | 507.88M | 411.99M | 349.21M | 348.48M | 346.51M |
| Interest Income | 6.33M | 489.00K | 570.00K | 985.00K | 1.44M |
| Interest Expense | 4.60M | 1.06M | 1.08M | 792.00K | 22.00K |
| Depreciation & Amortization | 21.11M | 18.27M | 15.29M | 13.23M | 12.17M |
| EBITDA | 126.59M | 101.74M | 78.30M | 90.10M | 91.00M |
| EBITDA Ratio | 20.87% | 20.57% | 19.03% | 21.25% | 21.39% |
| Operating Income | 98.83M | 83.47M | 63.02M | 76.87M | 78.83M |
| Operating Income Ratio | 16.29% | 16.87% | 15.31% | 18.13% | 18.53% |
| Total Other Income/Expenses | 2.06M | -1.14M | -346.00K | -314.00K | 2.61M |
| Income Before Tax | 100.89M | 81.53M | 61.94M | 76.55M | 81.44M |
| Income Before Tax Ratio | 16.63% | 16.48% | 15.05% | 18.05% | 19.15% |
| Income Tax Expense | 21.19M | 16.68M | 12.84M | 12.99M | 16.97M |
| Net Income | 79.70M | 64.85M | 49.10M | 63.56M | 64.47M |
| Net Income Ratio | 13.14% | 13.11% | 11.93% | 14.99% | 15.16% |
| EPS | 2.24 | 2.16 | 1.49 | 1.92 | 2.15 |
| EPS Diluted | 2.10 | 2.16 | 1.48 | 1.91 | 2.14 |
| Weighted Avg Shares Out | 35.61M | 33.12M | 33.12M | 33.12M | 30.13M |
| Weighted Avg Shares Out (Dil) | 37.98M | 33.18M | 33.21M | 33.22M | 30.11M |
Source: https://incomestatements.info
Category: Stock Reports